<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COPD exacerbations: Clinical manifestations and evaluation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COPD exacerbations: Clinical manifestations and evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COPD exacerbations: Clinical manifestations and evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H529081846"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The Global Initiative for Chronic Obstructive Lung Disease (GOLD), a report produced by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO), defines an exacerbation of chronic obstructive pulmonary disease (COPD) as "an event characterized by dyspnea and/or cough and sputum that worsens over ≤14 days, which may be accompanied by tachypnea and/or tachycardia, and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways" [<a href="#rid1">1,2</a>]. This generally includes an acute change in one or more of the following cardinal symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Cough increases in frequency and severity</p><p class="bulletIndent1"><span class="glyph">●</span>Sputum production increases in volume and/or changes character</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea increases</p><p></p><p>The clinical manifestations and evaluation of patients with exacerbations of COPD are discussed in detail here. A table to assist with emergency management of severe acute exacerbations of COPD is provided  (<a class="graphic graphic_table graphicRef65420" href="/z/d/graphic/65420.html" rel="external">table 1</a>). The diagnosis and treatment of stable COPD and the treatment, risk factors, prognosis, and prevention of exacerbations of COPD are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/120326.html" rel="external">"Stable COPD: Overview of management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/122145.html" rel="external">"COPD exacerbations: Prognosis, discharge planning, and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H4053711042"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Among patients with COPD, the frequency of exacerbation varies with the severity of disease, and some patients have more frequent exacerbations than others independent of other measures of disease severity [<a href="#rid1">1,3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Among almost 100,000 patients with COPD, the number of exacerbations in a baseline year of observation predicted the rate over the subsequent 10 years [<a href="#rid4">4</a>]. Approximately, 25 percent did not have an exacerbation; those with one baseline exacerbation were likely to have another (hazard ratio [HR] 1.71, 95% CI 1.66-1.77); and those with ≥5 events were even more likely to have future events (HR 3.41, 95% CI 3.27-3.56).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of Medicare beneficiaries found a 64 percent readmission rate after a discharge for a COPD exacerbation [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a survey that included over 4000 respondents with COPD, approximately 10 to 25 percent needed an emergency room evaluation for COPD and 5 to 10 percent required hospitalization [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate survey of more than 1000 patients, 21 percent of those who reported a COPD exacerbation required hospitalization [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H4282661352"><span class="h1">RISK FACTORS AND TRIGGERS</span></p><p class="headingAnchor" id="H545178851"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>According to observational studies, the risk of developing an exacerbation of COPD correlates with the following features [<a href="#rid8">8-19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age </p><p class="bulletIndent1"><span class="glyph">●</span>Productive cough</p><p class="bulletIndent1"><span class="glyph">●</span>Longer duration of COPD</p><p class="bulletIndent1"><span class="glyph">●</span>History of antibiotic therapy</p><p class="bulletIndent1"><span class="glyph">●</span>COPD-related hospitalization within the previous year</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic mucous hypersecretion</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood eosinophil count &gt;0.3<sup>4</sup> x 10<sup>9</sup> cells/L (340 cells/microL)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Use of medications leading to sedation or respiratory depression (including opioids, benzodiazepines, non-benzodiazepine hypnotics, and gabapentinoids)</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of one or more comorbidities (eg, ischemic heart disease, heart failure, or diabetes mellitus)</p><p></p><p>Women are slightly more likely to experience a COPD exacerbation than men [<a href="#rid13">13,20</a>]. In general, worsening airflow limitation (lower forced expiratory volume in one second [FEV<sub>1</sub>]) is associated with an increasing risk of COPD exacerbation, although airflow limitation alone does not provide a good assessment of exacerbation risk [<a href="#rid1">1</a>]. </p><p>Other potential contributors to an increased risk of exacerbations include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of COPD and history of prior</strong> <strong>exacerbations</strong> – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines suggest using primarily history of exacerbations, history of hospitalization for exacerbation, and symptoms to assess the exacerbation risk [<a href="#rid1">1</a>]. The number of exacerbations in the previous 12 months is stratified: a history of zero or one exacerbation suggests a low future risk of exacerbations, while two or more suggest a high future risk [<a href="#rid1">1</a>]. Symptoms (based on instruments such as the COPD Assessment Test [CAT] and the modified Medical Research Council Dyspnea Scale) further divide patients at low-risk into separate categories for more individualized pharmacologic management  (<a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">In the prospective Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, 2138 patients with moderate to severe airflow limitation (forced expiratory volume in one second [FEV<sub>1</sub>] &lt;80 percent predicted) were followed for three years [<a href="#rid21">21</a>]. The single best predictor of exacerbations was a history of prior exacerbations, regardless of severity of airway obstruction [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">Worsening airflow obstruction remains associated with an increasing prevalence of exacerbations, hospitalization, and death [<a href="#rid22">22</a>]. It is used as a component of the BODE index, a prognostic tool that can also be used to assess therapeutic response to medications, pulmonary rehabilitation therapy, and other interventions [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">Different COPD staging systems and severity assessments are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Assessment of severity and staging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroesophageal reflux disease</strong> – Gastroesophageal reflux disease (GERD) may be an additional risk factor for COPD exacerbations [<a href="#rid24">24,25</a>]. In the ECLIPSE study noted above, the occurrence of two or more exacerbations in a year was associated with a history of GERD or heartburn [<a href="#rid21">21</a>]. A similar observation was made in a case-control study that assessed the presence of GERD symptoms and frequency of COPD exacerbations in 80 patients with COPD. The presence of GERD symptoms was associated with an increased risk of COPD exacerbations (RR 6.55, 95% CI 1.86-23.11) [<a href="#rid24">24</a>]. However, in an observational study of 638 patients with stable COPD, therapy with proton pump inhibitors did not decrease the risk for severe exacerbations [<a href="#rid26">26</a>]. Additional studies are needed to determine whether GERD contributes to the development of COPD exacerbations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular diastolic dysfunction</strong> – Left ventricular diastolic dysfunction at baseline is associated with a higher frequency of hospitalization for COPD exacerbation [<a href="#rid27">27</a>]. Diastolic dysfunction is common in patients with COPD, likely due to both comorbid vascular mechanisms (eg, hypertension, coronary artery disease, systemic inflammation) as well as metabolic and structural consequences of COPD (eg, lung hyperinflation, chronic hypoxia, and hypercapnia) [<a href="#rid28">28,29</a>]. Many of these contributing factors worsen during an exacerbation and may lead to diastolic decompensation, followed by pulmonary congestion and bronchial hyper-reactivity [<a href="#rid30">30</a>]. High heart rates, whether due to breathlessness, anxiety, or atrial arrhythmias, further exacerbate this pathophysiology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension</strong> – Secondary pulmonary hypertension may be an additional risk factor for COPD exacerbations, possibly as an indicator of disease severity. In a follow-up to the ECLIPSE study, chest computed tomography scans were used to compute the ratio of the diameter of the pulmonary artery to the diameter of the aorta (PA:A ratio) [<a href="#rid31">31</a>]. In the study, a PA:A ratio greater than 1 was an independent risk factor for a future severe exacerbation (OR 3.44, 95% CI 2.78-4.25). Notably, a PA:A ratio &gt;1 suggests the presence of pulmonary hypertension, although it does not clarify the cause of pulmonary hypertension (eg, hypoxemia due to COPD or other lung disease, left heart failure, sleep apnea). The clinical usefulness of this observation in terms of treatment decisions is unclear.</p><p></p><p class="headingAnchor" id="H224733232"><span class="h2">Triggers</span><span class="headingEndMark"> — </span>Respiratory infections, most commonly viral (eg, rhinovirus) or bacterial, are estimated to trigger approximately 70 percent of COPD exacerbations  (<a class="graphic graphic_table graphicRef70203" href="/z/d/graphic/70203.html" rel="external">table 2</a>) [<a href="#rid1">1,32</a>]; atypical bacteria are a relatively uncommon cause [<a href="#rid33">33,34</a>]. The remaining 30 percent are due to environmental pollution, pulmonary embolism, or have an unknown etiology [<a href="#rid1">1,35-37</a>]. (See  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease"</a>.)</p><p>COPD exacerbations have been associated with exposure to poor outdoor air quality, such as higher levels of ozone, carbon monoxide, particulate matter (up to 10 microns), and nitrogen dioxide [<a href="#rid38">38,39</a>]. Increased ambient levels of fine particulate matter (≤2.5 microns, aka PM<sub>2.5</sub>) are associated with an increase in hospitalization and mortality in COPD [<a href="#rid40">40</a>]. In a trial of 116 patients with COPD and exposure to poor air quality at home (PM<sub>2.5</sub> &gt;10 mcg/m<sup>3</sup>), use of indoor air filters versus sham air filters resulted in a dose-dependent improvement in respiratory symptoms and risk of moderate exacerbations [<a href="#rid41">41</a>].</p><p>As dyspnea and cough are nonspecific symptoms, COPD exacerbations of unknown etiology may be triggered or caused by other medical conditions, such as myocardial ischemia, heart failure, aspiration, or pulmonary embolism [<a href="#rid1">1,42</a>].</p><p>The relationship between COPD exacerbation and pulmonary embolism is illustrated by a prospective multicenter study of 1580 patients with COPD who were admitted to the hospital with acute worsening of respiratory symptoms [<a href="#rid43">43</a>]. Pulmonary embolism was identified in 266 (17 percent) when all patients were screened with CT of the pulmonary arteries (CTPA); 166 patients (11 percent) had pulmonary embolism involving the main or lobar pulmonary arteries. The presence of new purulent sputum reduced the odds of pulmonary embolism. Although the frequency of pulmonary embolism among patients hospitalized with an exacerbation of COPD varies across studies [<a href="#rid44">44-47</a>], a systematic review prior to this multicenter study showed a similar pooled prevalence of 23 percent when all patients were evaluated by CTPA within 48 hours of hospital admission (seven studies, 999 patients) [<a href="#rid48">48</a>]. An important limitation of these studies is their inability to determine whether the pulmonary embolism is the cause of the COPD exacerbation, a result of the COPD exacerbation, or a mere bystander.</p><p class="headingAnchor" id="H1798631819"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of exacerbations of COPD range from a mild increase in dyspnea, cough that is productive or nonproductive to respiratory failure with acute respiratory acidosis and/or hypoxemia.</p><p class="headingAnchor" id="H3595964701"><span class="h2">Medical history</span><span class="headingEndMark"> — </span>By definition, patients present with the acute onset or worsening of respiratory symptoms, such as dyspnea, cough, and/or sputum production, over several hours to days [<a href="#rid1">1,49</a>]. These symptoms should be characterized further in terms of the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Time course of the symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Comparison to baseline level of symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Severity of respiratory compromise (eg, dyspnea at rest, dyspnea climbing stairs, dyspnea severity using a visual analog [1-10] scale)</p><p class="bulletIndent1"><span class="glyph">●</span>Delineation of sputum characteristics (eg, amount, color, purulence, blood)</p><p class="bulletIndent1"><span class="glyph">●</span>Use of home oxygen now or in the past</p><p></p><p>Associated features that might suggest an alternate diagnosis or comorbidity include:</p><p class="bulletIndent1"><span class="glyph">●</span>Constitutional symptoms (eg, fever, chills, night sweats)</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain, chest pressure, peripheral edema, or palpitations</p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for coronary disease</p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for thromboembolic disease </p><p class="bulletIndent1"><span class="glyph">●</span>Upper respiratory symptoms that might suggest a viral respiratory infection or exposure to anyone with influenza</p><p></p><p>Patients should be asked if they currently smoke cigarettes or use vaping products. The past history of exacerbations should be ascertained: number of prior exacerbations, courses of systemic glucocorticoids, antibiotic therapy in the preceding three months, prior exacerbations requiring hospitalization or ventilatory support, and response to therapy of previous exacerbations. </p><p class="headingAnchor" id="H3577228924"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical findings associated with an exacerbation of COPD often include wheezing and tachypnea and may include features of respiratory compromise such as difficulty speaking due to respiratory effort, use of accessory respiratory muscles, and paradoxical chest wall/abdominal movements (asynchrony between chest and abdominal motion with respiration). Tachycardia is also frequently present.</p><p>If present, decreased mental status could reflect hypercapnia or hypoxemia and asterixis could indicate hypercapnia.</p><p>Attention should also be paid to other physical findings, such as fever, hypotension, bibasilar fine crackles and peripheral edema, which might suggest a comorbidity or alternate diagnosis.</p><p class="headingAnchor" id="H4180675311"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The goals of the evaluation of a suspected exacerbation of COPD are to confirm the diagnosis, identify the cause (when possible), assess the severity of respiratory impairment and contribution from comorbidities, and exclude alternate diagnostic possibilities. A rapid overview for the evaluation and management of severe exacerbations of COPD is provided in the table  (<a class="graphic graphic_table graphicRef65420" href="/z/d/graphic/65420.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3169579089"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The choice of specific tests is guided by the severity of the exacerbation and the particular associated clinical findings. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>For patients with a mild exacerbation (absence of resting dyspnea or respiratory distress, preserved ability to perform activities of daily living), who do not require emergency department treatment, the evaluation may be limited to clinical assessment and possibly pulse oxygen saturation.</p><p>For patients who require emergency department care, the evaluation should generally include the following  (<a class="graphic graphic_table graphicRef65420" href="/z/d/graphic/65420.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of pulse oxygen saturation</p><p class="bulletIndent1"><span class="glyph">●</span>A chest radiograph to exclude pneumonia, pneumothorax, pulmonary edema, pleural effusion, followed by a chest CT angiogram to exclude pulmonary embolism in those whose chest radiograph does not reveal an acute process</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies (eg, complete blood count and differential, serum electrolytes and glucose)</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial blood gas (ABG) analysis is obtained if acute or acute-on-chronic respiratory acidosis is suspected or if ventilatory support is anticipated. Concern about acute-on-chronic hypercapnia might be prompted by a history of prior elevation in arterial tension of carbon dioxide (PaCO<sub>2</sub>), an elevated serum bicarbonate (perhaps reflecting compensation for chronic hypercapnia), or the presence of severe airflow obstruction (eg, forced expiratory volume in one second [FEV<sub>1</sub>] &lt;50 percent of predicted)</p><p></p><p>We do not use procalcitonin or C-reactive protein to determine the need for antibiotics in COPD exacerbations, as study results do not clearly and consistently demonstrate that either assay adds value to clinical judgment alone. (See  <a class="medical medical_review" href="/z/d/html/108592.html" rel="external">"Evaluation for infection in exacerbations of chronic obstructive pulmonary disease", section on 'Procalcitonin and C-reactive protein'</a>.)</p><p class="headingAnchor" id="H1622421326"><span class="h2">Additional testing</span><span class="headingEndMark"> — </span>Additional tests are largely used to exclude processes in the differential diagnosis and are obtained depending on the degree of diagnostic uncertainty following clinical evaluation and initial testing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram and blood cardiac troponins</strong> are obtained to evaluate tachycardia and/or potential myocardial ischemia. (See  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasma brain natriuretic peptide (BNP)</strong> or NT-proBNP can help to exclude heart failure, as indicated by features such as crackles on chest auscultation, peripheral edema, suggestive chest radiographic findings (eg, vascular congestion, pleural effusion). If the clinical picture is unclear, an echocardiogram should be obtained. (See  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest CT pulmonary angiogram</strong> can help exclude pulmonary embolism as a trigger or alternative diagnosis for respiratory symptoms. The frequency of pulmonary embolism in patients with COPD and acute respiratory symptoms in the hospital setting appears to be between 15 to 25 percent [<a href="#rid43">43,48</a>]. In one multicenter study of nearly 1600 patients hospitalized for COPD exacerbation who were assessed with CT pulmonary angiogram, the rates of pulmonary embolism based on low, moderate, or high probability Wells criteria scores were 7, 38, and 74 percent, respectively [<a href="#rid43">43</a>]. Purulent sputum production decreased the odds of venous thromboembolism by approximately 60 percent. Given this prevalence rate, we suggest obtaining imaging for pulmonary embolism (typically CT pulmonary angiogram) in patients with severe symptoms who do not have evidence of other triggers (eg, infection or heart failure). (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sputum Gram stain and culture</strong> are not obtained for most exacerbations of COPD. However, sputum Gram stain and culture can be useful in patients at risk for a poor outcome or increased risk of infection with <em>Pseudomonas </em> (<a class="graphic graphic_table graphicRef126161" href="/z/d/graphic/126161.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef126162" href="/z/d/graphic/126162.html" rel="external">table 4</a>). Sputum culture may be helpful in patients who are strongly suspected of having a bacterial infection but fail to respond to initial antibiotic therapy. (See  <a class="medical medical_review" href="/z/d/html/108592.html" rel="external">"Evaluation for infection in exacerbations of chronic obstructive pulmonary disease", section on 'When to obtain sputum studies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza testing </strong>is appropriate during influenza season or in patients with features of influenza (eg, acute onset of fever, myalgias, coryza during an influenza outbreak). Rapid antigen testing and direct or indirect immunofluorescence antibody staining tests are useful screening tests for influenza infection but have limited sensitivity; polymerase chain reaction (PCR)-based testing is more sensitive and specific. (See  <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – Test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (COVID-19) pandemic. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory virus panel in selected patients</strong> – The majority of COPD exacerbations are caused by viral infections, predominantly adenovirus. While not necessary in most patients, PCR diagnostic panels can detect multiple respiratory viruses simultaneously (eg, influenza, adenovirus, parainfluenza virus, respiratory syncytial virus, human metapneumovirus, coronavirus, and rhinovirus). These studies are more frequently obtained in patients with community-acquired pneumonia, and the exact indications for their use in COPD exacerbations are not clear. </p><p></p><p class="headingAnchor" id="H227814115"><span class="h2">Severity of exacerbation</span><span class="headingEndMark"> — </span>The classification of exacerbation severity proposed by an international commission and adopted by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) is based on symptoms, vital signs, and arterial blood gas (ABG) and c-reactive protein values (if obtained)  (<a class="graphic graphic_figure graphicRef140565" href="/z/d/graphic/140565.html" rel="external">figure 1</a>) [<a href="#rid1">1,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Dyspnea &lt;5 on a visual analog (1-10) scale (VAS); respiratory rate &lt;24 breaths per minute; heart rate &lt;95 beats per minute; resting SaO2 ≥92 percent breathing ambient air or the patient's usual oxygen prescription <strong>and</strong> change in saturation ≤3 percent from baseline (if known); CRP&lt;10 mg/L (if obtained). Treatment with short-acting bronchodilators is often sufficient for mild exacerbations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Three out of five of the following: Dyspnea ≥5 on VAS; respiratory rate ≥24 breaths per minute, heart rate ≥95 beats per minute; resting SaO2 &lt;92 percent breathing ambient air or the patient's usual oxygen prescription <strong>and/or</strong> change in saturation &gt;3 percent from baseline (if known); CRP ≥10 mg/L (if obtained). Treatment of moderate exacerbations generally includes short-acting bronchodilators plus antibiotics and/or oral glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Meets moderate criteria combined with hypercapnia and acidosis on ABG (PaCO2 &gt;45 mmHg <strong>and</strong> pH &lt;7.35). Treatment of severe exacerbations includes short-acting bronchodilators, antibiotics, and oral or intravenous glucocorticoids. Severe exacerbations may be associated with respiratory failure and require noninvasive or invasive ventilation.</p><p></p><p class="headingAnchor" id="H3179066035"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Patients with COPD who present to the hospital with acute worsening of dyspnea should be evaluated for potential alternative diagnoses, such as heart failure, cardiac arrhythmia, pneumonia, pulmonary embolism, and pneumothorax [<a href="#rid1">1,50,51</a>]. A chest radiograph will differentiate among several of these possibilities (eg, heart failure, pneumonia, pneumothorax); a clear chest radiograph may be a clue to pulmonary embolism, especially when dyspnea and hypoxemia are more prominent than cough or sputum production. </p><p>The importance of considering these alternate diagnoses was illustrated in an autopsy study of 43 patients with COPD who died within 24 hours of admission for a COPD exacerbation [<a href="#rid50">50</a>]. The primary causes of death were heart failure, pneumonia, pulmonary thromboembolism, and COPD in 37, 28, 21, and 14 percent, respectively. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – Acute decompensated heart failure (ADHF) is characterized by the development of acute dyspnea associated with elevated intracardiac filling pressures with or without pulmonary edema. HF may be new or an exacerbation of chronic disease. The diagnosis of ADHF is a clinical diagnosis based upon the presence of a constellation of symptoms and signs of HF. While test results (eg, natriuretic peptide level, chest radiograph, echocardiogram) are often supportive, the diagnosis cannot be based on a single test. (See  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac arrhythmias</strong> – Cardiac arrhythmias, such as atrial fibrillation, are frequent in patients with COPD, and may be a trigger or consequence of COPD exacerbation [<a href="#rid1">1</a>]. A bedside electrocardiogram can be diagnostic. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumonia</strong> – Pneumonia can present with acute shortness of breath, hypoxemia, and an inconclusive pulmonary examination. Chest radiograph findings may differ, but some cases of bibasilar pneumonia may be similar to HF, although evidence of upper zone redistribution is not present with pneumonia. Fever and leukocytosis may suggest an infectious process. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumothorax</strong> – COPD is a risk factor for pneumothorax. Worsening dyspnea can be due to either a COPD exacerbation or pneumothorax, but acute pleuritic chest pain would be more suggestive of pneumothorax while increased volume of sputum and sputum purulence would suggest a COPD exacerbation. A pneumothorax is usually apparent on conventional chest radiograph or thoracic ultrasound, although bullous emphysema can mimic a pneumothorax and necessitate a chest computed tomography (CT) scan for differentiation. (See  <a class="medical medical_review" href="/z/d/html/117242.html" rel="external">"Clinical presentation and diagnosis of pneumothorax"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary embolism</strong> – The sudden onset of symptoms such as dyspnea, pleuritic chest pain, tachypnea, and cough may be caused by a pulmonary embolism. The suspicion for pulmonary embolism rises in the absence of purulent sputum production, history of an upper respiratory infection, or pneumothorax [<a href="#rid42">42-48,52,53</a>]. (See <a class="local">'Triggers'</a> above and <a class="local">'Additional testing'</a> above.)</p><p></p><p class="bulletIndent1">Testing may include a blood D-dimer test, lower extremity compression ultrasonography with Doppler, and CT pulmonary angiogram. (See  <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p></p><p class="headingAnchor" id="H3110911250"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H3564663338"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – A COPD exacerbation is an event characterized by dyspnea and/or cough and sputum production that worsens over ≤14 days and is often associated with increased local and systemic inflammation arising from airway infection, pollution, or other insult to the airways. (See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management", section on 'Introduction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for exacerbations of COPD include advanced age, productive cough, duration of COPD, history of antibiotic therapy, COPD-related hospitalization within the previous year, chronic mucous hypersecretion, blood eosinophil count &gt;0.34 x 10<sup>9</sup> cells/L (340 cells/microL), and comorbid disease. The single best predictor of exacerbations is a history of prior exacerbations. (See <a class="local">'Risk factors and triggers'</a> above and  <a class="medical medical_review" href="/z/d/html/122145.html" rel="external">"COPD exacerbations: Prognosis, discharge planning, and prevention", section on 'Prognosis after an exacerbation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triggers</strong> – Respiratory infections are estimated to trigger approximately 70 percent of COPD exacerbations. Viral and bacterial infections are most common; atypical bacterial infection is an uncommon trigger. Other potential triggers include myocardial ischemia, heart failure, aspiration, and pulmonary embolism. (See <a class="local">'Triggers'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptoms</strong> – The three cardinal symptoms of COPD exacerbation are dyspnea, cough, and/or sputum production; they can occur alone or in combination. Exacerbations typically develop over several hours to days. Symptoms such as fever, chills, night sweats, chest pain, or peripheral edema suggest an alternate or comorbid diagnosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physical exam findings</strong> – Physical findings associated with an exacerbation of COPD often include wheezing and tachypnea and may include features of respiratory compromise. Patients should be examined for physical findings, such as fever, hypotension, bibasilar fine crackles and peripheral edema, which might suggest a comorbidity or alternate diagnosis. (See <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – For patients who require emergency department care, the evaluation should generally include a pulse oxygen saturation, chest radiograph, complete blood count and differential, and serum electrolytes and glucose  (<a class="graphic graphic_table graphicRef65420" href="/z/d/graphic/65420.html" rel="external">table 1</a>). Arterial blood gases (ABGs) are obtained when acute or acute-on-chronic hypercapnia is suspected due to prior elevation in arterial tension of carbon dioxide (PaCO<sub>2</sub>), an elevated serum bicarbonate, or the presence of severe airflow obstruction (eg, FEV<sub>1</sub> &lt;50 percent predicted). (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The most common processes in the differential diagnosis of a COPD exacerbation are heart failure, cardiac arrhythmias, pulmonary embolism, pneumonia, and pneumothorax. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Celli BR, Fabbri LM, Aaron SD, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021; 204:1251.</a></li><li><a class="nounderline abstract_t">Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418.</a></li><li><a class="nounderline abstract_t">Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2018; 198:464.</a></li><li><a class="nounderline abstract_t">Lindenauer PK, Dharmarajan K, Qin L, et al. Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2018; 197:1009.</a></li><li><a class="nounderline abstract_t">Landis SH, Muellerova H, Mannino DM, et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis 2014; 9:597.</a></li><li><a class="nounderline abstract_t">Miravitlles M, Anzueto A, Legnani D, et al. Patient's perception of exacerbations of COPD--the PERCEIVE study. Respir Med 2007; 101:453.</a></li><li><a class="nounderline abstract_t">Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67:495.</a></li><li><a class="nounderline abstract_t">Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006; 130:1096.</a></li><li><a class="nounderline abstract_t">Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131:20.</a></li><li><a class="nounderline abstract_t">Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135:975.</a></li><li><a class="nounderline abstract_t">Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 2016; 193:965.</a></li><li><a class="nounderline abstract_t">Oshagbemi OA, Keene SJ, Driessen JHM, et al. Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013. Respir Med 2018; 144:1.</a></li><li><a class="nounderline abstract_t">Rahman AA, Dell'Aniello S, Moodie EEM, et al. Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease : A Population-Based Cohort Study. Ann Intern Med 2024.</a></li><li><a class="nounderline abstract_t">Rong Y, Bentley JP, McGwin G, et al. Association Between Transient Opioid Use and Short-Term Respiratory Exacerbation Among Adults With Chronic Obstructive Pulmonary Disease: A Case-Crossover Study. Am J Epidemiol 2019; 188:1970.</a></li><li><a class="nounderline abstract_t">Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging 2013; 30:183.</a></li><li><a class="nounderline abstract_t">Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2014; 44:332.</a></li><li><a class="nounderline abstract_t">Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2016; 48:683.</a></li><li><a class="nounderline abstract_t">Castaneda JM, Hee Wai T, Spece LJ, et al. Risks of Zolpidem among Patients with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2024; 21:68.</a></li><li><a class="nounderline abstract_t">Stolz D, Kostikas K, Loefroth E, et al. Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink Data. Chest 2019; 156:674.</a></li><li><a class="nounderline abstract_t">Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128.</a></li><li><a class="nounderline abstract_t">Soriano JB, Lamprecht B, Ramírez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med 2015; 3:443.</a></li><li><a class="nounderline abstract_t">Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005.</a></li><li><a class="nounderline abstract_t">Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008; 63:951.</a></li><li><a class="nounderline abstract_t">Kim J, Lee JH, Kim Y, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med 2013; 13:51.</a></li><li><a class="nounderline abstract_t">Baumeler L, Papakonstantinou E, Milenkovic B, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology 2016; 21:883.</a></li><li><a class="nounderline abstract_t">Bhatt SP, Agusti A, Bafadhel M, et al. Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2023; 208:1026.</a></li><li><a class="nounderline abstract_t">López-Sánchez M, Muñoz-Esquerre M, Huertas D, et al. High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study. PLoS One 2013; 8:e68034.</a></li><li><a class="nounderline abstract_t">Farouk H, Albasmi M, El Chilali K, et al. Left ventricular diastolic dysfunction in patients with chronic obstructive pulmonary disease: Impact of methods of assessment. Echocardiography 2017; 34:359.</a></li><li><a class="nounderline abstract_t">Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013; 162:237.</a></li><li><a class="nounderline abstract_t">Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367:913.</a></li><li><a class="nounderline abstract_t">Sapey E, Bafadhel M, Bolton CE, et al. Building toolkits for COPD exacerbations: lessons from the past and present. Thorax 2019; 74:898.</a></li><li><a class="nounderline abstract_t">Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.</a></li><li><a class="nounderline abstract_t">Mohan A, Chandra S, Agarwal D, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology 2010; 15:536.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269.</a></li><li><a class="nounderline abstract_t">Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax 2006; 61:250.</a></li><li><a class="nounderline abstract_t">Gan WQ, FitzGerald JM, Carlsten C, et al. Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. Am J Respir Crit Care Med 2013; 187:721.</a></li><li><a class="nounderline abstract_t">de Miguel-Díez J, Hernández-Vázquez J, López-de-Andrés A, et al. Analysis of environmental risk factors for chronic obstructive pulmonary disease exacerbation: A case-crossover study (2004-2013). PLoS One 2019; 14:e0217143.</a></li><li><a class="nounderline abstract_t">Ross BA, Doiron D, Benedetti A, et al. Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort. Thorax 2023; 78:974.</a></li><li><a class="nounderline abstract_t">Li MH, Fan LC, Mao B, et al. Short-term Exposure to Ambient Fine Particulate Matter Increases Hospitalizations and Mortality in COPD: A Systematic Review and Meta-analysis. Chest 2016; 149:447.</a></li><li><a class="nounderline abstract_t">Hansel NN, Putcha N, Woo H, et al. Randomized Clinical Trial of Air Cleaners to Improve Indoor Air Quality and Chronic Obstructive Pulmonary Disease Health: Results of the CLEAN AIR Study. Am J Respir Crit Care Med 2022; 205:421.</a></li><li><a class="nounderline abstract_t">Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144:390.</a></li><li><a class="nounderline abstract_t">Liu X, Jiao X, Gong X, et al. Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study. Int J Chron Obstruct Pulmon Dis 2023; 18:907.</a></li><li><a class="nounderline abstract_t">Pourmand A, Robinson H, Mazer-Amirshahi M, Pines JM. Pulmonary Embolism Among Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: Implications For Emergency Medicine. J Emerg Med 2018; 55:339.</a></li><li><a class="nounderline abstract_t">Hassen MF, Tilouche N, Jaoued O, Elatrous S. Incidence and Impact of Pulmonary Embolism During Severe COPD Exacerbation. Respir Care 2019; 64:1531.</a></li><li><a class="nounderline abstract_t">Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA 2021; 325:59.</a></li><li><a class="nounderline abstract_t">Jiménez D, Agustí A, Tabernero E, et al. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial. JAMA 2021; 326:1277.</a></li><li><a class="nounderline abstract_t">Sato R, Hasegawa D, Nishida K, et al. Prevalence of pulmonary embolism in patients with acute exacerbations of COPD: A systematic review and meta-analysis. Am J Emerg Med 2021; 50:606.</a></li><li><a class="nounderline abstract_t">Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196.</a></li><li><a class="nounderline abstract_t">Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009; 136:376.</a></li><li><a class="nounderline abstract_t">Myint PK, Lowe D, Stone RA, et al. U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration 2011; 82:320.</a></li><li><a class="nounderline abstract_t">Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009; 135:786.</a></li><li><a class="nounderline abstract_t">Aleva FE, Voets LWLM, Simons SO, et al. Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD: A Systematic Review and Meta-analysis. Chest 2017; 151:544.</a></li></ol></div><div id="topicVersionRevision">Topic 122144 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.goldcopd.org" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570991" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603117" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29474094" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29206052" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24944511" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16938447" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Patient's perception of exacerbations of COPD--the PERCEIVE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11070451" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035443" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Role of gastroesophageal reflux symptoms in exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218552" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk indexes for exacerbations and hospitalizations due to COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017866" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641631" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30366578" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38224592" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease : A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31361012" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Association Between Transient Opioid Use and Short-Term Respiratory Exacerbation Among Adults With Chronic Obstructive Pulmonary Disease: A Case-Crossover Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23371396" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24743966" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418553" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incident opioid drug use and adverse respiratory outcomes among older adults with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37916873" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risks of Zolpidem among Patients with Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31103696" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843247" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Susceptibility to exacerbation in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25995071" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999112" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18535116" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23927016" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26970108" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37560988" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23826360" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28165145" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Left ventricular diastolic dysfunction in patients with chronic obstructive pulmonary disease: Impact of methods of assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23727296" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chronic obstructive pulmonary disease and cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22938715" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary arterial enlargement and acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31273049" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Building toolkits for COPD exacerbations: lessons from the past and present.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038881" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Infection in the pathogenesis and course of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415983" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10911010" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16517585" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : COPD exacerbations . 2: aetiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23392442" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31120946" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Analysis of environmental risk factors for chronic obstructive pulmonary disease exacerbation: A case-crossover study (2004-2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37147124" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111257" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Short-term Exposure to Ambient Fine Particulate Matter Increases Hospitalizations and Mortality in COPD: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34449285" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Randomized Clinical Trial of Air Cleaners to Improve Indoor Air Quality and Chronic Obstructive Pulmonary Disease Health: Results of the CLEAN AIR Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549851" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37223656" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29945817" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pulmonary Embolism Among Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: Implications For Emergency Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31387893" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Incidence and Impact of Pulmonary Embolism During Severe COPD Exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33399840" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34609451" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34879475" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence of pulmonary embolism in patients with acute exacerbations of COPD: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492164" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318666" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21597277" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812453" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27522956" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD: A Systematic Review and Meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
